A5070166134- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Ion channel regulation and function
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Neurological disorders and treatments
- ECG Monitoring and Analysis
- Parkinson's Disease Mechanisms and Treatments
- Receptor Mechanisms and Signaling
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Syncope and Autonomic Disorders
- Cardiomyopathy and Myosin Studies
- Dementia and Cognitive Impairment Research
- Cardiovascular and exercise physiology
- Neurogenetic and Muscular Disorders Research
- Cardiovascular Health and Risk Factors
- Mitochondrial Function and Pathology
- Cardiovascular Effects of Exercise
- Mechanical Circulatory Support Devices
- Cardiac Arrest and Resuscitation
- Heart Rate Variability and Autonomic Control
- Cardiac Imaging and Diagnostics
- Viral Infections and Immunology Research
- Health, Environment, Cognitive Aging
University of Rochester Medical Center
2016-2025
University of Rochester
2010-2024
University of Makati
2024
University of Utah
2024
Spencer Foundation
2024
Cleveland Clinic
2022
Boston Scientific (United States)
2021
Virginia Commonwealth University
2020
Atrium Health Wake Forest Baptist
2020
Sheba Medical Center
2018
One form of the hereditary long-QT syndrome, LQT3-Delta KPQ, is associated with sustained inward sodium current during membrane depolarization. Ranolazine reduces late channel current, and we hypothesized that ranolazine would have beneficial effects on electrical mechanical cardiac function in LQT3 patients SCN5A-DeltaKPQ mutation.We assessed 8-hour intravenous infusions (45 mg/h for 3 hours followed by 90 5 hours) ventricular repolarization myocardial relaxation SCN5A-Delta KPQ mutation....
Background— Atrial fibrillation (AF) requires arrhythmogenic changes in atrial ion channels/receptors and usually altered structure. AF is commonly treated with antiarrhythmic drugs; the most effective block many channels/receptors. Modest efficacy, intolerance, safety concerns limit current drugs. We hypothesized that combining agents multiple anti-AF mechanisms at reduced individual drug doses might produce synergistic efficacy plus better tolerance/safety. Methods Results— HARMONY tested...
Background : We conducted a study of chronic therapy with flecainide versus placebo in small group LQT‐3 patients the ΔKPQ deletion to evaluate safety and efficacy this genetic disorder. In vitro studies have shown that provides correction impaired inactivation associated deletion. Methods: A randomized, double‐blind, placebo‐controlled clinical trial was six male subjects Results: The lowest possible dose at least 40 ms reduction QTc interval determined an initial open‐label, dose‐ranging...
Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs).This study aimed to determine whether ranolazine administration decreases the likelihood of VT, VF, or death an ICD.This was double-blind, placebo-controlled clinical trial which high-risk ICD ischemic nonischemic cardiomyopathy were randomized 1,000 mg twice day placebo. The primary endpoint VT VF requiring appropriate therapy death,...
In transiently transfected mammalian cells we have identified pharmacological consequences of a naturally occurring deletion mutation, ΔKPQ, the human heart Na + channel α subunit that previously has been linked to one form long QT syndrome, an inherited disease. Our results show Class I B antiarrhythmic agent lidocaine blocks maintained inward current through and slows recovery from inactivation ΔKPQ-encoded channels. Block is greater for than peak current. Because incomplete mutant...
QT interval prolongation and torsades de pointes ventricular tachycardia have been reported after therapeutic doses overdosage of second generation antihistamines, such terfenadine astemizol. Diphenhydramine (DPHM), a first H1 antagonist, is the most frequently used antihistaminic drug. Despite its widespread use, there are no data about cardiac action electrocardiographic consequences DPHM overdose. The 12-lead electrocardiograms 126 patients (mean age 26 ± 11 years) who had overdose were...
We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total 84 patients with advanced HF underwent percutaneous transseptal implantation sensor. Quarterly noninvasive calibration by modified Valsalva maneuver was achieved all patients, 96.5% sessions were successful reproducibility 1.2 mmHg. Absolute sensor drift maximal after 3 months at 4.7 mmHg (95% CI, 3.2–6.2 mmHg) remained stable...
Background: Long QT syndrome (LQTS) is caused by the abnormal function of ion channels, which may also affect atrial electrophysiology and be associated with risk fibrillation (AF). However, large-scale studies AF among patients LQTS its relation to manifestations are lacking. We aimed assess relationship genotype long-term prognosis in LQTS. Methods: Genotype-positive (784 LQT1, 746 LQT2, 233 LQT3) were compared 2043 genotype-negative family members. Information on occurrence was based...
<h3>Objective</h3> To assess mexiletine9s long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1). <h3>Methods</h3> We performed randomized, double-blind, placebo-controlled trial mexiletine (150 mg 3 times daily) to evaluate its efficacy homogenous adult ambulatory DM1. The primary outcome was change at 6 months. Secondary outcomes included changes hand grip myotonia, strength, swallowing, forced vital capacity, lean...
<h3>Importance</h3> Current guidelines for primary implantable cardioverter-defibrillator (ICD) therapy do not account sex differences in arrhythmic risk ICD candidates. <h3>Objective</h3> To evaluate the association between and of ventricular tachyarrhythmia (VTA) mortality. <h3>Design, Setting, Participants</h3> This cohort study compared VTA mortality 4506 men women enrolled 4 Multicenter Automatic Defibrillator Implantation Trials (MADIT) July 1, 1997, December 31, 2011. Data from...
Prospective data regarding the role of implantable cardioverter-defibrillator (ICD) for primary prevention sudden cardiac death in patients with long QT syndrome (LQTS) is scarce. Herein, we explore prospective Rochester LQTS ICD registry to assess risk appropriate shock a real-world setting. We studied 212 that had implantation prevention. Best-subsets proportional-hazards regression analysis was used identify clinical variables were associated first shock. Conditional models Prentice,...
The effectiveness of implantable cardioverter-defibrillators (ICDs) on reducing mortality has not been well studied in patients with long QT syndrome (LQTS).
Sex-specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life-threatening (LTEs) postadolescent women with LQTS. In the present study, we aimed to develop personalized estimates burden of CEs LTEs male adolescents potassium channel-mediated